The SABER® and Cloud™ Injectable Depot Systems
  ORADUR® Oral Delivery System
  TRANSDUR® Transdermal Technology System
  DURIN® System
  Localized Drug Delivery
  Patents
  Publications





SABER®-Bupivacaine Reduced Pain Intensity for 72 Hours Following Abdominal Surgery Relative to Bupivacaine-HCI. T. Gan, A. Yang, N. Verity, D. Ellis. 2014 Annual Meeting of the American Society of Anesthesiologists. October 11, 2014.

SABER®-Bupivacaine Reduces Postoperative Pain Intensity and Opioid Use for 72 Hours in Soft-Tissue and Bony Surgeries. J. Moodie, O. Radke, D. Ellis, N. Verity, A. Yang, S. Rasmussen. 2014 Annual Meeting of the American Society of Anesthesiologists. October 15, 2014.

The PK Profile of SABER®-Bupivacaine in Humans Across Surgical Models Demonstrates Sustained 72-Hour Drug Delivery. J. Shah, N. Verity, A. Yang. 2014 Annual Meeting of the American Society of Anesthesiologists. October 15, 2014.

SABER®-Bupivacaine Concurrently Reduces Postoperative Pain Intensity and Opioid Use for 72 Hours: Evaluation of CROPIRS Scores. R. Watts, H. Wulf, N. Verity, A. Yang, A. Ekelund. 2014 Annual Meeting of the American Society of Anesthesiologists. October 15, 2014.

Cardiac Safety of SABER®-Bupivacaine in Patients Undergoing Abdominal Surgery in the BESST Trial: An Assessment of Holter Monitoring Data from the BESST Trial. T. Gan, A. Fossa, M. Zhou, D. Ellis, J. Shah, C. Hartrick, R. Watts. 39th Annual American Society of Regional Anesthetic and Pain Medicine Meeting. April 5, 2014.

Efficacy and Safety of SABER®-Bupivacaine Local Anesthetic in Open Hernia Repair. R. Watts, D. Ellis, N. Verity, A. Yang, R. Turner. 39th Annual American Society of Regional Anesthetic and Pain Medicine Meeting. April 5, 2014.

Treatment of Postoperative Pain in Shoulder Surgery with SABER®-Bupivacaine. A. Ekelund, A. Peredistijs, J. Grohs, D. Ellis, N. Verity, A. Yang, S. Rasmussen. 39th Annual American Society of Regional Anesthetic and Pain Medicine Meeting. April 5, 2014.

Treatment of Postoperative Pain in Major Abdominal Surgery with SABER®-Bupivacaine: Results of the BESST Trial. T. Gan, H. Papaconstantinou, M. Durieux, N. Singla, S. Johna, D. Lissin, N. Verity, D. Ellis, H. Minkowitz. 39th Annual American Society of Regional Anesthetic and Pain Medicine Meeting. April 5, 2014.

Pharmacokinetic Characteristics of SABER®-Bupivacaine in Humans Demonstrate Sustained Drug Delivery for up to 72 Hours in a Variety of Surgical Models. J. Shah, D. Ellis, N. Verity. 39th Annual American Society of Regional Anesthetic and Pain Medicine Meeting. April 5, 2014.

Treatment of postoperative pain in shoulder surgery with SABER®-Bupivacaine. Ellis D, Verity N, Lissin D, Wendicke-Lophaven K. American Pain Society 32nd Annual Scientific Meeting, May 8, 2013.

The Abuse Potential of Remoxy®, an Extended-Release Formulation of Oxycodone, Compared with Immediate- and Extended-Release Oxycodone. Setnik B, Roland C, Cleveland L, Webster L. Pain Medicine 2011; 12: 618-631.

Remoxy®: A Novel Formulation of Extended-Release Oxycodone Developed Using the ORADUR® Technology. Zamloot M, Chao W, Ling-Ling K, Ross J, Fu R. The Journal of Applied Research, Vol.10, No.3, 2010.

SABER™ Bupivacaine, a novel extended-release formulation of bupivacaine for postoperative pain control demonstrates dose-response, safety and no impact on surgical wound healing following inguinal herniorrhapy. Hadj A, Nicholson D, Moodie J, Turner R, Watts R, Abrouk N, Langecker P, Lissin D. American College of Surgeons 95th Annual Clinical Congress, October 12, 2009.

SABER™ Formulation for Intra-Articular Delivery of rhGH. Sekar M, Okumo F, van Osdol W, Tamraz W, Tung D, Sverdrup F. The American Association of Pharmaceutical Scientists 2009 National Biotechnology Meeting, June 21-25, 2009.

Clinical Trial Results: A Randomized, Double-Blind, Placebo-Controlled Trial of a Three-Day Bupivacaine Patch (ELADUR™) in Patients with Post-Herpetic Neuralgia. Wallace MS, Kudrow DB, McElveen WA, Drass MJ, Webster LR, Huddlestone JJ, Reynolds LW, Lissin DV, Langecker P. The American Pain Society 27th Annual Meeting, May 8, 2008.

Post-Operative Pain Control with Extended-Release Bupivacaine Formulation. Clinical Trial Results in Inguinal Hernia Repair. Nicholson D., Brown C., Turner R., Hadj A., Watts R., Shah J., Abrouk N., Lissin D., Langecker P. American Hernia Society, March 15, 2008.

Intracranial drug-delivery scaffolds: Biocompatibility evaluation of sucrose acetate isobutyrate gels. J Lee, GI Jallo, MB Penno, KL Gabrielson, GD Young, RM Johnson, EM Gillis, C Rampersaud, BS Carson, M Guarnieri. Toxicol Appl Pharmacol. 2006, April 19

DUROS® Osmotic Pharmaceutical Systems for Parenteral & Site-Directed Therapy. J. Wright, S. Yum, RM. Johnson Drug Delivery Technology Magazine 2003 Vol 3 No 1: 64-73.

Implantable Osmotic Pump Providing Continuous Subcutaneous Delivery of Sufentanil for Chronic Pain, D. Fisher, Presented at the 2nd World Congress of World Institute of Pain. June 27-30, 2001; Istanbul, Turkey, Symposium.

Pharmacokinetic Advantage of Intrapericardially Applied Substances in the Rat. J. Hermans, H. Van Essen, H. Struijker-Boudier, R. Johnson, F. Theeuwes, J. Smits. The Journal of Pharmacology and Experimental Therapeutics. 2002; 301: 672-678.

Applications of Continuous Site-Directed Drug Delivery. R. Johnson, A. Verity. Proceedings of the Western Pharmacology Society. 2002; 45: 219-222.

A New Drug Delivery Catheter For Surgically Eloquent Tissue. E. Gillis, M. Guarnieri, B. Carson, P. Storm, R. Clatterbuck, Y. Liu, C. Rampersaud, R. Johnson. Presented at the 2nd International Symposium on Tumor Targeted Delivery Systems, Sept 2002; A:35.

Evaluation of the SABER Delivery System for the Controlled Release of Deslorelin: Effect of Dose in Estrogen Primed Ovarectomized Gilts. R. Barb, R. Kraeling, G. Rampacek, D. Thompson, Jr., J. Gibson, S. Sullivan, B. Simon, and P.J. Burns. Presented at the 26th International International Meeting of The Controlled Release Society, 1999, June 20-25, Boston, Massachusetts.

Induction of Mucosal IgA Specific for SeMF3 of Streptococcus equi with Intranasal Vaccination Using a Sucrose Acetate Isobutyrate Based Delivery System. J. Nally, S. Artiushin, A. Sheoran, J. Timoney, J. Gibson, S. Sullivan, R. Gilley, B. Simon, and P.J. Burns. Presented at the 26th International Meeting of The Controlled Release Society, 1999, June 20-25, Boston, Massachusetts.

Pharmacodynamic Evaluation of Biodegradable Estradiol-17b Microspheres and Prostaglandin F2a for the control of Estrus and Ovulation in Gilts. R. Cushman, J.H. Britt, P. Davis, U. Boonyaprakob, V. Hedgpeth, J. Gibson, B. Hudson, and P.J. Burns. Presented at the 25th International Meeting of The Controlled Release Society, 1998, June 21-26, Las Vegas, Nevada.

Sustained Release of Progesterone and Estradiol From the SABER TM Delivery System: In Vitro and In Vivo Release Rates. S.A. Sullivan, J.W. Gibson, P.J. Burns, L. Franz, E.L. Squires, D.L. Thompson, and A.J. Tipton. Presented at the 25th International Meeting of The Controlled Release Society, 1998, June 21-26, Las Vegas, Nevada.

Evaluation of the SABERTM Delivery System for the Controlled Release of the GnRH Analog Deslorelin for Advancing Ovulation in Mares: Effect of Gamma Radiation. R. Betschart, J. Fleury, E.L. Squires, T. Nett, J. Gibson, S. Sullivan, A. Tipton, and P.J. Burns. Presented at the 25th International Meeting of The Controlled Release Society, 1998, June 21-26, Las Vegas, Nevada.

Evaluation of the SABERTM Delivery System for the Controlled Release of Deslorelin for Advancing Ovulation in the Mare: Effects of Formulation & Dose. J. Fleury,. E.L. Squires, R. Betschart, J. Gibson, S. Sullivan, A. Tipton, and P.J. Burns. Presented at the 25th International Meeting of The Controlled Release Society, 1998, June 21-26, Las Vegas, Nevada.

Pharmacodynamic Evaluation of the SABERTM Delivery System for the Controlled Release of the GnRH Analogue Deslorelin Acetate for Advancing Ovulation in Cyclic Mares. P. Burns, D. Thompson, F. Donadue, L. Kincald, B. Leise, J. Gibson, R. Swaim, and A. Tipton. Presented at the 24th International Meeting of The Controlled Release Society, 1997, June 16-19, Stockholm.

Evaluation of the Saber Delivery System for the Release of GnRH Analog Deslorelin Acetate for Advancing Ovulation in the Mare. F.J. Donadue, D.L. Thompson, P.J. Burns, A.J. Tipton, J.W. Gibson, R.P. Swaim, L.A. Kincald, and B.S. Leise. Presented at the 15th Annual Meeting of The Equine Nutrition and Physiology Society Meeting, 1997, May 29-31, Fort Worth, Texas.

Controlled Release of Heparin from Vascular Grafts Over a 55 Day Period. E. Espinal, J. Bulgrin, M. Chapman, S. Schmidt, and A. J. Tipton. American College of Surgeons Meeting, 1995, March 13-16, Akron, Ohio.



 
 © 2000-2014 DURECT Corporation
Last updated: October 24, 2014
Search     Contact     Site Index     Legal Notice     Privacy Policy